TDO2 and neoplasm: Inhibition of tumor- or immunosuppressive cell-expressed GLS1, ARG1, iNOS, IDO1, TDO and/or IL4I1 therefore constitutes a promising approach to alleviate tumor-induced immune suppression, either as monotherapy or in combination with other treatment modalities.